S

Singular Genomics Systems Inc
NASDAQ:OMIC

Watchlist Manager
Singular Genomics Systems Inc
NASDAQ:OMIC
Watchlist
Price: 22.97 USD 0.39% Market Closed
Market Cap: 57.4m USD
Have any thoughts about
Singular Genomics Systems Inc?
Write Note

Intrinsic Value

OMIC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one OMIC stock under the Base Case scenario is 74.41 USD. Compared to the current market price of 22.97 USD, Singular Genomics Systems Inc is Undervalued by 69%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OMIC Intrinsic Value
74.41 USD
Undervaluation 69%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation Backtest
Singular Genomics Systems Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for OMIC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about OMIC?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Life Sciences Tools & Services Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Singular Genomics Systems Inc

Provide an overview of the primary business activities
of Singular Genomics Systems Inc.

What unique competitive advantages
does Singular Genomics Systems Inc hold over its rivals?

What risks and challenges
does Singular Genomics Systems Inc face in the near future?

Has there been any significant insider trading activity
in Singular Genomics Systems Inc recently?

Summarize the latest earnings call
of Singular Genomics Systems Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Singular Genomics Systems Inc.

Provide P/S
for Singular Genomics Systems Inc.

Provide P/E
for Singular Genomics Systems Inc.

Provide P/OCF
for Singular Genomics Systems Inc.

Provide P/FCFE
for Singular Genomics Systems Inc.

Provide P/B
for Singular Genomics Systems Inc.

Provide EV/S
for Singular Genomics Systems Inc.

Provide EV/GP
for Singular Genomics Systems Inc.

Provide EV/EBITDA
for Singular Genomics Systems Inc.

Provide EV/EBIT
for Singular Genomics Systems Inc.

Provide EV/OCF
for Singular Genomics Systems Inc.

Provide EV/FCFF
for Singular Genomics Systems Inc.

Provide EV/IC
for Singular Genomics Systems Inc.

Show me price targets
for Singular Genomics Systems Inc made by professional analysts.

What are the Revenue projections
for Singular Genomics Systems Inc?

How accurate were the past Revenue estimates
for Singular Genomics Systems Inc?

What are the Net Income projections
for Singular Genomics Systems Inc?

How accurate were the past Net Income estimates
for Singular Genomics Systems Inc?

What are the EPS projections
for Singular Genomics Systems Inc?

How accurate were the past EPS estimates
for Singular Genomics Systems Inc?

What are the EBIT projections
for Singular Genomics Systems Inc?

How accurate were the past EBIT estimates
for Singular Genomics Systems Inc?

Compare the revenue forecasts
for Singular Genomics Systems Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Singular Genomics Systems Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Singular Genomics Systems Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Singular Genomics Systems Inc compared to its peers.

Compare the P/E ratios
of Singular Genomics Systems Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Singular Genomics Systems Inc with its peers.

Analyze the financial leverage
of Singular Genomics Systems Inc compared to its main competitors.

Show all profitability ratios
for Singular Genomics Systems Inc.

Provide ROE
for Singular Genomics Systems Inc.

Provide ROA
for Singular Genomics Systems Inc.

Provide ROIC
for Singular Genomics Systems Inc.

Provide ROCE
for Singular Genomics Systems Inc.

Provide Gross Margin
for Singular Genomics Systems Inc.

Provide Operating Margin
for Singular Genomics Systems Inc.

Provide Net Margin
for Singular Genomics Systems Inc.

Provide FCF Margin
for Singular Genomics Systems Inc.

Show all solvency ratios
for Singular Genomics Systems Inc.

Provide D/E Ratio
for Singular Genomics Systems Inc.

Provide D/A Ratio
for Singular Genomics Systems Inc.

Provide Interest Coverage Ratio
for Singular Genomics Systems Inc.

Provide Altman Z-Score Ratio
for Singular Genomics Systems Inc.

Provide Quick Ratio
for Singular Genomics Systems Inc.

Provide Current Ratio
for Singular Genomics Systems Inc.

Provide Cash Ratio
for Singular Genomics Systems Inc.

What is the historical Revenue growth
over the last 5 years for Singular Genomics Systems Inc?

What is the historical Net Income growth
over the last 5 years for Singular Genomics Systems Inc?

What is the current Free Cash Flow
of Singular Genomics Systems Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Singular Genomics Systems Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Singular Genomics Systems Inc

Current Assets 148.7m
Cash & Short-Term Investments 133.4m
Receivables 440k
Other Current Assets 14.9m
Non-Current Assets 71.3m
PP&E 69.6m
Other Non-Current Assets 1.7m
Current Liabilities 16.9m
Accounts Payable 1.5m
Accrued Liabilities 11.1m
Other Current Liabilities 4.3m
Non-Current Liabilities 65.3m
Long-Term Debt 6.4m
Other Non-Current Liabilities 59m
Efficiency

Earnings Waterfall
Singular Genomics Systems Inc

Revenue
2.7m USD
Cost of Revenue
-3.8m USD
Gross Profit
-1.1m USD
Operating Expenses
-98.3m USD
Operating Income
-99.5m USD
Other Expenses
7.6m USD
Net Income
-91.9m USD

Free Cash Flow Analysis
Singular Genomics Systems Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 2024, Singular Genomics focused on developing the G4X Spatial Sequencer, offering advanced readouts and improved throughput. Revenue reached $0.7 million, including sales of two G4 instruments. Despite enhancements, the company reported a net loss of $21.3 million. Cash reserves stood at $133.2 million, with a cash burn of $17.5 million, reduced from previous quarters. They plan an early access program for G4X by year-end 2024, with a commercial launch in mid-2025, aiming to address spatial biology needs and expand their market.

What is Earnings Call?
Fundamental Scores

OMIC Profitability Score
Profitability Due Diligence

Singular Genomics Systems Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
Exceptional 1-Year Revenue Growth
Declining ROE
21/100
Profitability
Score

Singular Genomics Systems Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

OMIC Solvency Score
Solvency Due Diligence

Singular Genomics Systems Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
52/100
Solvency
Score

Singular Genomics Systems Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OMIC Price Targets Summary
Singular Genomics Systems Inc

Wall Street analysts forecast OMIC stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OMIC is 9.66 USD with a low forecast of 6.57 USD and a high forecast of 13.07 USD.

Lowest
Price Target
6.57 USD
71% Downside
Average
Price Target
9.66 USD
58% Downside
Highest
Price Target
13.07 USD
43% Downside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for OMIC?

Click here to dive deeper.

Dividends

Singular Genomics Systems Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for OMIC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

OMIC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Singular Genomics Systems Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

57.2m USD

Dividend Yield

0%

Description

Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. The company is headquartered in La Jolla, California and currently employs 221 full-time employees. The company went IPO on 2021-05-27. The firm has developed an NGS technology or sequencing engine. The company is developing two integrated solutions that are built to target specific applications. The firm's first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which is collectively referred as G4 Integrated Solution. The G4 Instrument is a sequencer designed to produce accurate genetic sequencing results. Its second integrated solution in development comprises an instrument and an associated menu of consumable kits, which is collectively referred as PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a multiomics solution.

Contact

CALIFORNIA
La Jolla
10931 N Torrey Pines Rd Ste 100
+18583337830.0
singulargenomics.com

IPO

2021-05-27

Employees

221

Officers

Founder, CEO, President & Chairperson of the Board
Mr. Andrew Spaventa
Founder, Member of Scientific Advisory Board & Independent Director
Dr. David L. Barker Ph.D.
Founder, Chief Scientific Officer & Chair of Scientific Advisory Board
Dr. Eli N. Glezer Ph.D.
Chief Financial Officer
Mr. Dalen Meeter
Chief Operating Officer
Dr. Jyotsna Ghai Ph.D.
Senior VP, General Counsel & Secretary
Mr. Eric Stier
Show More
Head of Sales
Mr. Jeff Bullard
Head of Human Resources
Mr. Vincent Brancaccio
Chief Business Officer
Mr. Jorge Velarde Jr., MBA
Show Less

See Also

Discover More
What is the Intrinsic Value of one OMIC stock?

The intrinsic value of one OMIC stock under the Base Case scenario is 74.41 USD.

Is OMIC stock undervalued or overvalued?

Compared to the current market price of 22.97 USD, Singular Genomics Systems Inc is Undervalued by 69%.

Back to Top